November 28, 2017
CTI Clinical Trial & Consulting Services Welcomes and Announces Promotions of Directors of Regulatory Affairs and Real World Evidence & Late Phase Research
FOR IMMEDIATE RELEASE [Covington, KY ~ November28, 2017]
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization is pleased to welcome John Adams and Alex Almond as Director, Regulatory Affairs and Senior Director, Business Development-Real World Evidence, respectively, and to announce the promotion of Matthew Hodskins to Director, Consulting Business Development.
"We are thrilled to welcome both John and Alex to the CTI team, and to announce Matt's promotion" said Jim Westerkamp, Vice-President, Consulting. "As our business continues to expand, all three will play critical roles in the leadership and development of their respective departments."
John Adams, PharmD - Director, Regulatory Affairs
Dr. Adams comes to CTI with 20 years of experience in the clinical research industry. Most recently, he served as Senior Director, Clinical Development at Humacyte. Prior to that role, John also served as Senior Director, Clinical Development at INC Research, Director of Clinical Research at Social & Scientific Systems, Director of Scientific Affairs and Pharmacovigilance at PharmaResearch Corporation, Medical Liaison, Virology at Roche Laboratories, and as a Clinical Research Scientist at Gilead Sciences.
He will be supporting the CTI Consulting group with regulatory submission documents, regulatory agency interactions, drug development plans, and other Consulting projects.
John completed a 3-year postdoctoral fellowship in antiviral clinical pharmacology in 1997 after earning his Doctor of Pharmacy from the University of Buffalo.
Alex Almond - Senior Director, Business Development-Real World Evidence & Late Phase Research
Alex Almond comes to CTI with more than 15 years of business development/sales experience with the last 7 years focused in the Health Economics and Outcomes Research space. Most recently, he held the position of Senior Director, Business Development with Dymaxium. Prior to that role, Alex Almond held similar positons with Doctor Evidence and OptumInsight. He will be supporting the business development activities of the CTI Real World Evidence and Late Phase Research Team.
Alex earned his Bachelor of Arts in Health and Physical Education from Bridgewater College.
Matthew Hodskins - Director, Consulting Business Development, Consulting
Matt came to CTI in April 2001 as a member of CTI's Research Associate program. He then joined the ranks of the Project Management group within Consulting, where he established himself as a valuable resource to his internal and external customers. Since then, he has worked with the Consulting team on a wide variety of projects, including serving as the Assistant Director, Project and Proposals Management, a role in which he managed all proposals and Project Managers for the Consulting group.
In his new role as Director, Consulting Business Development, Matt will manage the Consulting sales team as they continue to expand service offerings, and will contribute to the development of the overall vison of the group.
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com